Overview

An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese

Status:
Completed

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

The part A of N01362 is to evaluate the bioequivalence of Levetiracetam (LEV) 1500 mg intravenous (iv) infusion when compared to tablet oral administration in Chinese healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Pharma

Treatments:

Etiracetam
Levetiracetam
Piracetam